Skip to main content
Premium Trial:

Request an Annual Quote

Violaine Mélen, Stéphane Cruveiller

PathoQuest has appointed Violaine Mélen as its head of quality assurance and regulatory affairs. In the new position, Mélen will oversee the maintenance of product quality and compliance in line with the firm's quality management system, while also leading the firm's regulatory strategies. She has more than 12 years of experience in regulatory affairs, quality assurance, and clinical affairs within the biotech and pharmaceutical industries. Mélen previously worked at Bio-Rad Laboratories where she was responsible for implementing risk management procedures with a specific focus on infectious disease.

In addition, PathoQuest has appointed Stéphane Cruveiller as its chief technology information officer. As CTIO, Cruveiller will be responsible for the technical aspects of the firm's bioinformatics pipeline and alignment information technology-related development initiatives with its business goals. Cruveiller previously served as team leader at the François Jacob Institute of Biology - Genoscope of the French Alternative Energies and Atomic Energy Commission at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.